December 2021

Harbour BioMed Investor Relations

02142.HK



CONTENTS

01.Global Roadshow	01
02.Product Update	03
03.HBM as a Thought Leader	04
04.HBM Overview	05
05.Hong Kong Biopharma Industry	07
06.Global Market Overview	08



In November, Harbour BioMed presented at Goldman Sachs Asian Pacific Healthcare Forum 2021, 12th Credit Suisse China Investment Conference Changing Gears, and NDRs organized by Morgan Stanley





Attended **20+** NDRs in November





Industrial Securities

Annual Capital Market Summit 2022



> 兴证全球基金 | 兴证国际 | 兴证资管 | 兴证期货 | 兴证资本 兴证投资 | 兴证风险管理 | 兴证全球资本 | 兴证慈善 | 海峡股交

China Securities

Annual Capital Market Summit 2022

14:10—14:50 ▶ 以核心技术平台为引擎,引领中国创新药发展 和铂医药董事长 王劲松



中信建投证券
2022年度资本市场峰会

BioCentury

8th China Healthcare Summit



CHINA HEALTHCARE SUMMIT

The Bridge to Innovation

Organized by BioCentury & BayHelix in collaboration with McKinsey & Co.

NOV. 16-19, 2021 HYBRID EVENT



The development of fully-human antibody-drug conjugates (ADC) between Harbour BioMed and Kelun-Biotech are advancing at full speed

> With continuous technology breakthroughs, ADC with its unique therapeutic value has gradually become a novel and fast-growing sector. Harbour BioMed leverages its fully-human antibody platforms to collaborate with Kelun-Biotech to develop novel fully-human antibody-drug conjugates targeting two cutting-edge targets in oncology diseases.





03 HBM as a Thought Leader

Dr. Hong Que: The Role of Polysorbate in Formulation of Biologics

Dongwu Entrepreneur Pharmacy Forum



Polysorbate is a common excipient used in the formulation of Biologics.

In this lecture, three aspects are introduced:

- 1) Polysorbate's role in Biologics Formulation
- 2) Polysorbate can undergo a variety of degradation reactions
- 3) Quality control of Polysorbate

"东吴企业家药学论坛"第五期第54讲


讲座主题:聚山梨酯在生物药制剂中的作用与控制策略
主讲人:阙红,博士、首席技术官,和铂医药
时间: 2021年11月30日(周二),18:30-19:30
地点:腾讯会议(731-133-607)
主持人:许国强,教授、副院长






	Key Information
Website – Investor Access	https://www.harbourbiomed.com/investor
Market Cap (11/30, Mil HK\$)	7,026
Total Share Capital (Mil)	768
Circulation Stock (Mil)	768

In November, the Hong Kong stock indexes went down. Compared to first trading day this month, the Hang Seng Index and the Hang Seng Composite Index dropped by 6.7% and 4.7%, respectively. The healthcare sector rebounded slightly. The Hang Seng Healthcare Index rose 0.7%. With a strong stock performance, Harbour BioMed saw a largest one-day increase by 10.6% and surged by 34.8% compared to first trading day this month.



HBM Stock Performance – November



HBM Overview (02142.HK)

Company News


- **O1** The development of fully-human antibody-drug conjugates (ADC) between Harbour BioMed and Kelun-Biotech are advancing at full speed
- HBM Holdings (02142.HK) was up more than 5% approaching market close. The company surged more than 45% accumulatively in the past eight days. A new clinical research of HBM4003 injection was announced for the first time
- Choose the difficult and right thing to do snowball KOL research on Harbour BioMed
- China's AFC Ajax in innovative therapeutics Harbour BioMed research
- **05** Harbour BioMed: 3 Unique fully human antibody platforms! Focusing immuno-oncology differentiated therapeutics which are about to enter commercialization
- Harbour BioMed, a pearl of China's innovative medicine
- **17** Snowball KOL research: Harbour BioMed, choose the difficult and right thing to do
- A differentiated drug leader in innovative medicine Harbour BioMed
- **09** Fully human antibody platforms. It takes several years for a new drug to complete the journey from initial discovery to the marketplace





Market Overview

In November, the HSCI closed at 3680.2, down 4.7%. The HSHCI closed at 5386.3, up 0.7%. The China Hong Kong Biotech index (CESHKB.CSI) closed at 12086.2, down 4.5%.



HK Listing Biopharma Companies (18A)

Closing Price 2021/11/01 Closing Price 2021/11/30

O Global Market Overview

Global Market Index					
		Closing Price			
	2021.11.01	2021.11.15	2021.11.30		
Dow Jones Industrial	35913.8	36087.5	34483.7		
Nasdaq Composite	15596.0	15853.9	15537.7		
UK FTSE 100	7288.6	7351.9	7059.5		
German DAX	15806.3	16148.6	15100.1		
France CAC40	6893.3	7128.6	6739.4		

HK Market Index				
	Closing Price			
	2021.11.01	2021.11.15	2021.11.30	
Hang Seng Index	25154.3	25390.2	23475.3	
Hang Seng Composite Index	3860.7	3905.4	3680.2	
Hang Seng Tech Index Index	6279.4	6601.2	6028.3	
HS China Enterprise	8899.3	9085.6	8368.5	
Hang Seng Healthcare Index	5350.0	5537.2	5386.3	

Major Global Economic Indicators – August						
Country	Related Indicator	Estimated	Actual			
US	Number of Unemployment Benefits Initial Claiming for the week of 11/24 (1k people)	26.0	19.9			
US	The Index of Consumer Sentiment of the University of Michigan	72.4	66.8			
Eurozone	Sentix Investor Confidence	15.5	18.3			
Germany	ZEW Economic Sentiment	20.0	31.7			
Germany	Gfk Consumer Confidence	-1.0	-1.6			

• The WHO states "the possibility of potential spread of Omicron at the global level is high".

• The European Central Bank executive committee Fabio Panetta said that the Fed's interest rate hike does not mean that the European Central Bank will also raise interest rates. The Vice President Luis de Guindos also said that the European Central Bank will continue to provide support measures.

• The EIA report shows that the US Strategic Petroleum Reserve (SPR) inventories fell to the lowest level since June 2003. The nation's commercial crude oil inventories excluding strategic reserves increased by 1.017 million barrels to 434 million barrels, rose 0.2%.

• The Bank of Korea raised its benchmark interest rates by 25 basis points to 1%, in line with market expectations.

HARBOUR BIOMED



Harbour BioMed is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE[™]) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating H2L2, HCAb, HBICE with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.



Harbour BioMed

ir@harbourbiomed.com www.harbourbiomed.com linkedin: https://www.linkedin.com/company/13244036/admin/